HTB

World AIDS 20 Melbourne 2014

20th International AIDS Conference, 20-25 July 2014, Melbourne

Update on baseline STIs in UK oral PrEP study (PROUD)

High prevalence of COPD at baseline in START study sub-study

Risk of CVD or type-2 diabetes according to change in BMI after starting ART

Rosuvastatin may be partially effective in moderating residual immune activation on ART

Reasons for loss to follow up in the Malawi Option B+ programme

20th International AIDS Conference, 20-25 July 2014, Melbourne

The loss of friends and colleagues from flight MH 17

Higher ART coverage is associated with lower HIV infection rates in a multi-country analysis

Pill A, Pill B: simplified second-line treatment for low-income countries

UNAIDS sets 90-90-90 target for 2020 to end AIDS by 2030

No difference in overall anaemia rate with reduced dose AZT

Open label oral PrEP at four doses a week: why zero infections does not equal 100% efficacy

Cure research at IAS 2014: TILDA measures the reservoir and romidepsin wakes it up

HIV and transgender issues at AIDS 2014

Transgender services and clinics: interviews at AIDS 2014 with JoAnne Keatley and Beatriz Grinsztejn

Publications launched at AIDS 2014